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catalysts allows cells to carry out complex and thermody-
namically unfavorable chemical conversions. In an effort to
recruit these advantages for in vitro biotransformations, we
have assembled a 10-step catalytic system—a system of
biotransformations (SBT)—for the synthesis of unnatural
monosaccharides based on the versatile building block
dihydroxyacetone phosphate (DHAP). To facilitate the
assembly of such a network, we have insulated a production
pathway from Escherichia coli’s central carbon metabolism.
This pathway consists of the endogenous glycolysis without
triose-phosphate isomerase to enable accumulation of
DHAP and was completed with lactate dehydrogenase to
regenerate NADþ. It could be readily extended for the
synthesis of unnatural sugar molecules, such as the unna-
tural monosaccharide phosphate 5,6,7-trideoxy-D-threo-
heptulose-1-phosphate from DHAP and butanal. Insulation
required in particular inactivation of the amn gene encoding
the AMP nucleosidase, which otherwise led to glucose-
independent DHAP production from adenosine phos-
phates. The work demonstrates that a sufficiently insulated
in vitro multi-step enzymatic system can be readily
assembled from central carbon metabolism pathways.
Biotechnol. Bioeng. 2010;106: 376–389.
 2010 Wiley Periodicals, Inc.
KEYWORDS: cell-free synthesis; carbohydrate synthesis;
multi-enzyme catalysis; dihydroxyacetone phosphate; aldo-
laseIntroduction
Cell-free systems are a promising approach for the
implementation of novel complex biochemical functions
(Forster and Church, 2007; Jewett et al., 2008; Meyer et al.,
2007). The absence of physical barriers such as membranesCorrespondence to: S. Panke
376 Biotechnology and Bioengineering, Vol. 106, No. 3, June 15, 2010and their specific transportation mechanisms allows for
direct substrate supply and access to the product and
the catalytic system, enabling facilitated monitoring and
manipulation, and the application of user-defined condi-
tions (Hold and Panke, 2009).
The downsides of these advantages are typically a loss of
catalytic complexity and the inability of the system to repair
itself. However, the former issue can be successfully
addressed by either in vitro re-assembling of multi-member
systems from purified components or by using cell-free
extracts (CFXs). Purified systems allow an unsurpassed
degree of reaction control (e.g., Fessner and Walter, 1992;
Nahalka et al., 2003; Shimizu et al., 2001; Welch and Scopes,
1985; Zhang et al., 2007), and have been successfully used in
tasks as complex as in vitro protein production (Shimizu
et al., 2001). The obvious drawback is currently the
laborious purification of the parts. Reaction systems based
on CFXs, which only remove the cellular transport barrier,
have been exploited to similar degrees of complexities
(Mureev et al., 2009; Swartz, 2006), but frequently suffer
from undesired background reactions (Kim and Swartz,
2000, 2001), which in turn might be eliminated in selectively
mutated strains (Calhoun and Swartz, 2006; Knapp et al.,
2007).
The problem of undesired background reactions is
exemplified in the central carbon metabolism of bacteria,
which has a number of molecules as intermediates that
could be of ample use in fine-chemical syntheses such
as dihydroxyacetone phosphate (DHAP), phosphoenol
pyruvate (PEP; Enders et al., 2008), pyruvate (PYR; Zelic
et al., 2003) and erythrose-4-phosphate (E4P; Sheflyan et al.,
1998), but at the same time is a highly interconnected
reaction network with ample possibilities to interfere
with designed reaction pathways. Of the various interesting
targets, DHAP is central to the production of a stereo-
chemically complete set of vicinal diols and its chemical
or biochemical synthesis has therefore received a lot of 2010 Wiley Periodicals, Inc.
attention (Herk et al., 2009; Schu¨mperli et al., 2007). We
therefore investigated whether glycolysis as a part of central
carbon metabolism could be adapted for the in vitro
production of DH AP from cheap glucose (GLC).Material and Methods
Chemicals
NADþ and NADH were from Gerbu (Heidelberg,
Germany), yeast extract and peptone from BD Bioscience
(Basel, Switzerland), ATP and purified enzymes from Roche
Diagnostics (Rotkreuz, Switzerland), except myokinase and
rabbit muscle aldolase (RAMA; Sigma–Aldrich, Buchs,
Switzerland). All other chemicals were from Sigma–Aldrich.Strains and Growth Condition
Escherichia coli W3110 (ATCC 27325) and two derivatives,
the knockout strains W3110 tpiA::kan and W3110 tpiA::kan
amn, were used in this study. W3110 tpiA::kan was
constructed by phage l red recombination as described
previously (Datsenko and Wanner, 2000). The tpiA gene was
replaced by a kanamycin resistance gene (Datsenko and
Wanner, 2000) flanked by 40 bp segments that were
homologous to the tpiA gene using the upstream primer
50-GTTAAGGCGAAGAGTTAAGGAAAGTAAGTGCCGGA-
TATGA-30 and the downstream primer 50-CGTGGA-
GAATTAAAATGCGACATCCTTTAGTGATG GGTAA-30.
W3110 tpiA::kan amn was constructed by removing the
kanamycin resistance gene from W3110 tpiA::kan and
subsequent P1-transduction (Miller, 1992) of the amn::kan
mutation from W3110 amn::kan (Baba et al., 2006).
Knockouts were verified by PCR using appropriate primers.
The strains were grown in Luria–Bertani broth. For
fermentations M9-GYE (M9 mineral medium supplemen-
ted with 4 g L1 GLC and 5 g L1 yeast extract) was used. LB
and M9 media were prepared as described elsewhere
(Sambrook and Russel, 2001). Kanamycin was added to
50mg mL1.Fermentation and Preparation of CFX
Fermentations were carried out as fed-batch fermentations
using M9-GYE medium. An overnight culture in the same
medium plus kanamycin was used for inoculation of 3 L of
medium in a 5 L bioreactor equipped as described earlier
(Valsesia et al., 2007) to an initial OD600 of 0.5. The
fermentation was started in batch mode and the feed
(100 g L1 yeast extract, 50 g L1 GLC, 22.2 mM MgSO4)
was started after the culture had entered stationary phase (as
indicated by a rise in the dissolved oxygen tension). The
feeding rate was controlled manually such that the dissolved
oxygen concentration never fell below 40% of saturation toprevent oxygen limitation. Aeration was set to 3 L min1
(1 vvm) and stirrer speed to 800 rpm during batch phase.
They were increased during the feed-phase to 1,000 rpm and
5 L min1 to increase oxygen transfer. Fermentations were
stopped at an OD600 of 18–20 corresponding to 6–6.6 g L
1
of cell dry weight (CDW), which yielded sufficient CFX for
our experiments. Cells were then harvested by centrifugation
at 12,000g for 30 min at 48C and re-suspended in 10 mM
phosphate buffer pH 7.0 (2 mL g1 of cell wet weight). Then,
cells were lysed in a high pressure homogenizer (Haskel,
Wesel, Germany) twice at a pressure drop of 1,000 bar over
the orifice at 88C. Cell debris and insoluble components
were removed by centrifugation at 25,000g for 45 min at
48C. The supernatant was used as CFX and applied either
directly or stored at 808C. Where indicated, the CFX was
further treated by washing using a centrifugation-dependent
ultrafiltration unit (Sartorius, Dietikon, Switzerland) with a
molecular weight cut off of 10 kDa. The buffer was
exchanged by consecutive dilution and concentration steps
with 10 mM phosphate buffer using a total of at least five
sample volumes.Reaction Conditions
Multi-enzyme reactions were performed in a liquid volume
of 10 mL in thermostated double-jacketed beakers at 378C.
CFX was diluted into reaction buffer (final composition
100 mM NaHCO3 pH 7.7; 5 mM MgCl2; 0.8 mM KCl;
11.1 mM GLC; 11.1 mM sodium phosphate pH 7.7) to a
final protein concentration of 1 or 10 mg mL1. NADþ and
lactate dehydrogenase (LDH) were added to different
concentrations depending on the experimental setup.
Reactions were started by adding ATP to a final concentra-
tion between 2.875 and 23 mM as indicated. ATP degrada-
tion experiments were performed similarly but without GLC
in the reaction buffer. Samples were taken at indicated time
points and the reaction was stopped by adding an equal
volume of isopropanol and immediate chilling on ice.
Proteins were removed by centrifugation and the super-
natant was used after appropriate dilution with water for
further analysis. Experiments with 13C1-labeled GLC were
performed as described above for unlabeled GLC.
The formation of 5,6,7-trideoxy-D-threo-heptulose-1-
phosphate (TDHP) was carried out in an aliquot of
10 mL (10 mg mL1 CFX in 100 mM NaHCO3 pH 7.7, 5 mM
MgCl2, 0.8 mM KCl, 0.575 mM NAD
þ, 1 U mL1 LDH,
11.1 mM or 55.5 mM GLC, and 11.1 or 55.5 mM sodium
phosphate pH 7.0), DHAP production from GLC was
started by adding ATP to a final concentration of 2.875 mM.
Butanal was added to produce TDHP via a one-step or a
two-step process. For a one-step process, butanal (1 mmol)
and RAMA (10 U) were added before starting the reaction;
for a two-step process the components were added after an
initial DHAP-production phase of 30 min. Additional
butanal pulses were added as described in the text.Bujara et al.: DHAP Production in a System of Biotransformations 377
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Analytics
Protein concentrations were determined as described
previously (Bradford, 1976). All mentioned CFX concen-
trations refer to the concentration of total protein in the
reaction system. The metabolites ATP, ADP, and AMP
(summarized as AXP) and DHAP were analyzed in 96-well
plates using an enzymatic assay reported previously
(Bergmeyer et al., 1984) but downscaled to 200mL. GLC
was analyzed using a commercial enzyme kit (R-Biopharm,
Darmstadt, Germany), also downscaled to 200mL. All these
assays relied on a final measurement of the rate of NADþ/
NADH conversion based on the change in absorption at
340 nm, which was recorded on a 96-well plate reader
(Perkin Elmer, Waltham, Massachusetts). The additional
enzymes required for the assay were added using an
automatic dispenser (Perkin Elmer). Absolute concentra-
tions were calculated from previously prepared standard
curves. In graphical representations for reactions containing
10 mg mL1 of total protein, the calculated GLC concentra-
tion of 11.1 mM at addition of ATP is shown rather than the
first value measured a few seconds later (t¼ 0), because the
inevitable period between reaction start and first sampling
was sufficient to consume substantial portions of the initially
added GLC. The initial specific production rate of DHAP
was determined from the period of linear increase in DHAP
concentrations. All results are the average of two parallel
reactions, with each reaction analyzed in triplicate so
that error bars represent the standard deviation of six
measurements.
The ratio between 12C1-DHAP and
13C1-DHAP was
determined by mass spectrometry operated in the negative
mode. After enzyme inactivation (see above), the sample was
further diluted 1:250 in MeOH:H2O (3:1) to give a final
dilution of 1:1,000 and then analyzed by ESI-MS (MDS Sciex
4000 Q-Trap; Applied Biosystems, Foster City, CA) using
continuous direct injection with a syringe pump at
30mL min1 (general settings: ion spray voltage¼
4,200 V; curtain gas¼ 15; collision gas¼ 4; temperature¼
2008C; ion source gas 1¼ 30; ion source gas 2¼ 40; values
without units represent arbitrary instrument-specific units).
The 12C- and 13C-DHAP signal was measured using the
signal intensity of the phosphate fragment (m/z¼ 97) of the
mother ions of 12C-DHAP (m/z¼ 169) and 13C-DHAP (m/
z¼ 170; declustering potential¼25 V; collision energy¼
14 V; cell exit potential¼15 V).
NADH stability and glucose-6-phosphate dehydrogenase
(G6P-DH) activity were analyzed using the same 96-well
plate reader system described above. An aliquot of 10mL
of 50 mM NADH in water was added to 200mL of
CFX (protein concentration of 1 mg mL1 in 100 mM
NaHCO3 pH 7.7, 5 mM MgCl2, 0.8 mM KCl) and
absorption at 340 nm was measured every 10 s. To analyze
the stability of the NADþ regeneration capacity, CFX
(composition as before) was incubated at 378C for different
periods of time and then chilled on ice. NADH was added to
aliquots of 200mL, the reaction was incubated at 378C for378 Biotechnology and Bioengineering, Vol. 106, No. 3, June 15, 201010 min and then absorption at 340 nm was recorded. Results
are the average of three parallel reactions.
The analysis of the G6P-DH activity was disturbed by
remaining NADH-oxidation capacity of the CFX (see
below). To circumvent this, samples were pre-incubated for
2 h at 378C (at which temperature G6P-DH is stable;
Murakami et al., 2006), but not the rest of the cellular
NADH-oxidation capacity, see below). An aliquot of 10mL
of G6P (50 mM in water) was added to 200mL of CFX (1 or
10 mg mL1 in 100 mM NaHCO3, pH 7.7, 5 mM MgCl2,
0.8 mM KCl, and NADPþ or NADþ as indicated) and
absorption at 340 nm was measured every 5 s. The specific
activity was determined by linear regression. Results are the
average of three parallel reactions.
For the quantification of TDHP, for which no commercial
standard was available, we synthesized the reference
compound in a 1 mL aliquot from commercially available
DHAP by incubation of the reaction mixture (25 mM
DHAP; 100 mM butanal; 1 U mL1 RAMA; in water) at
378C for 1 h. The reaction was terminated by filtration
through an ultrafiltration unit (Sartorius, Dietikon,
Switzerland) with a molecular weight cut off of 10 kDa.
DHAP was quantified before and after the reaction as
described above, and the difference was set as the
concentration of TDHP in the sample as reported previously
for calculating conversion rates (Fessner and Sinerius, 1994;
Wong and Whitesides, 1983). A standard curve for TDHP
(in 75% MeOH; 25% water; 2 mM formic acid; 5 mM
ammonium formate, 4mM 3-(N-morpholino)propanesul-
fonic acid (MOPS) was recorded using ESI-MS analysis (see
above). The constant signal of the phosphate fragment of
TDHP (m/z¼ 241; declustering potential¼60 V; collision
energy¼19 V; cell exit potential¼15 V) was normalized
against the constant m/z¼ 80 fragment signal of MOPS (m/
z¼ 208; declustering potential¼65 V; collision energy¼
40 V; cell exit potential¼11 V) in order to compensate
for day-to-day variations of total signal intensities. Samples
from TDHP synthesis were diluted appropriately (in 75%
MeOH; 25% water; 2 mM formic acid; 5 mM ammonium
formate, 4mM MOPS) and the normalized signal was used
for quantification using the standard curve.Results
A ‘‘System of Biotransformations’’ (SBT) for the
Production of DHAP—A Multi-Enzyme Pathway
With Balanced Cofactor Recycling Derived From
E. coli ’s Glycolysis
The enzymes of bacterial glycolysis can convert cheap GLC
in vitro to a variety of interesting building blocks, in
particular DHAP for the synthesis of vicinal diols
(Schu¨mperli et al., 2007). In addition to the conversion
of the carbon skeleton, such a multi-enzyme route involves
the consumption of cofactors such as ATP and consequently
requires cofactor regeneration. Figure 1 illustrates one
possible multi-enzyme route based on E. coli’s glycolysis.
The crucial step is the cleavage of fructose-1,6-bisphosphate
(FBP, please refer to Fig. 1 for a list of abbreviations)
into DHAP and glyceraldehyde-3-phosphate (GAP). In
wild-type (WT) glycolysis, DHAP is isomerized by triose-
phosphate-isomerase (TpiA) to GAP and enters the lower
part of glycolysis. Hence, the knockout of the tpiA gene is
essential for the accumulation of DHAP, which in turn
reduces the flux through the lower part of glycolysis by a
factor of two to one molecule of GAP per mole of GLC.
A theoretically cofactor-balanced enzyme system for the
production of DHAP from GLC via glycolysis consists of
10 enzymatic reactions which can be grouped into
3 subsystems: (i) the upper part of glycolysis which is theFigure 1. An SBT for unnatural carbohydrate synthesis via DHAP-dependent aldolase
model reaction chosen in this study is catalyzed by FBA and RAMA. Note that TpiA is knocke
dotted lines represent multiple reactions. HK, hexokinase; PGI, phosphoglucose isomerase; P
isomerase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; PGK, phosphoglycerate
lactate dehydrogenase; FucA, fuculose aldolase; RhuA, rhamnulose aldolase; TagA, t
glucose; G6P, glucose-6-phosphate; F6P, fructose-6-phosphate; FBP, fructose-1,6-bisph
1,3PG, 1,3!diphosphoglycerate; 3PG, 3-phosphoglycerate; 2PG, 2-phosphoglycerate; PEP,
6PG, 6-phospho-gluconate; RL5P, ribulose-5-phosphate; R5P, ribose-5-phosphate; X5P,
triphosphate; ADP, adenosine-diphosphate; AMP, adenosine-monophosphate; AXP, sum of
adenine dinucleotide phosphate; TDHP, 5,6,7-trideoxy-D-threo-heptulose-1-phosphate.production pathway from GLC to DHAP and GAP
(4 reactions, 2 molecules of ATP converted to ADP); (ii)
the lower part of glycolysis from GAP to PYR, building the
ATP regeneration pathway (5 reactions, 1 molecule of
NADþ converted to NADH, 1 molecule of Pi consumed,
2 molecules of ATP generated from ADP); and (iii) the
LDH-based NADþ/NADH regeneration system (1 reaction,
1 molecule of NADH converted to NADþ). An evaluation of
the thermodynamics of the SBT based on tabulated
Gibbs energy values under standard conditions and at pH
7 indicates that the reaction should proceed easily to
completion (data not shown).
In living cells, G6P is primarily produced during the
import of GLC by the PTS, which requires PEP as a cofactor
and is partly membrane-located. The application of a cell-s and a schematic overview of different routes leading to the formation of DHAP. The
d in the DHAP producing SBT. Solid lines represent a single enzyme catalyzed reaction,
FK, phosphofructokinase; FBA, frcuctosebisphosphate aldolase; TpiA, triosephosphate
kinase; GPM, phosphoglycaerate mutase; ENO, enolase; PK, pyruvate kinase; LDH,
agatose aldolase; iRAMA, rabbit muscle aldolase; Amn, AMP-nucleosidase; GLC,
osphate; DHAP, dihydroxyacetone phosphate; GAP, glyceraldehyde-3-phosphate;
phosphoenolpyruvate; PYR, pyruvate; LAC, lactate; 6PGL, 6-phosphogluconolactone;
xylulose-5-phosphate; E4P, erythrose-4-phosphate; A, adenine; ATP, adenosine-
adenosine phosphates; NAD, nicotinamide adenine dinucleotide; NADP, nicotinamide
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free system (see below) raised the question whether or not
the addition of a soluble hexokinase-type of reaction (either
from gene expression in the cultured strain or as an addition
at the in vitro stage) is required. Literature data on the
regulation of the endogenous E. coli glucokinase (GLK)
indicated that it would be present after cultivation on yeast
extract supplemented mineral medium with GLC as the
carbon source (Meyer et al., 1997). We will refer to this
multi-enzyme sequence for the production of DHAP with
complete cofactor regeneration as the SBT.
The following parts address the general applicability of
recruiting a highly interconnected pathway from central
carbon metabolism for the synthetic purpose of a SBT.Implementation of the Reaction Network
For the generation of an SBT for the production of DHAP, a
tpiA knockout mutant was constructed in E. coli W3110.
Since the mutant is strongly impaired in growth on mineral
medium with GLC as the sole carbon source, yeast
extract was added (M9-GYE). The tpiA::kan mutant was
still hampered in growth on M9-GYE (mmax¼ 0.4 h1 in
exponential growth phase) compared to the WT strain
W3110 (mmax¼ 0.8 h1). Cultivations were carried out as
fed-batch fermentations and harvested cells were homo-
genized to produce CFX.
To test the feasibility of DHAP accumulation in a single
knockout mutant, CFX from the tpiA mutant was diluted to
a total protein concentration of 1 mg mL1. As a control, we
used CFX derived from the WT W3110 strain grown under
the same conditions. To eliminate any potential limitations
for DHAP production by cofactor regeneration at this stage,
we added LDH (1 U mL1) and then the cofactors (ATP:
11.5 mM and NADþ: 5.75 mM) in half-stoichiometric
amounts relative to GLC (11.1 mM). Both the WT and
the tpiA::kan mutant-derived CFXs consumed the entire
GLC provided in 125–175 min (Fig. 2A). However, only the
tpiA-derived CFX accumulated 8.3 mM DHAP within 5 h,
which was about 65-fold higher than in the WT-derived
CFX (Fig. 2A). The SBT showed stable operation for a period
of 10 h in a continuous system as steady-state DHAP
concentrations only showed minor changes (data not
shown).
In principle, the use of crude CFX could lead to the
production of DHAP from sources other than GLC, such as
from metabolites being present in the CFX, by degradation
of macromolecules (DNA, RNA, or proteins) or along
pathways other than the selected SBT. However, when the
SBT was operated with 13C1-labeled GLC, 90% of the
produced DHAP was labeled, indicating that the major part
of the produced DHAP was indeed derived from GLC along
the SBT (Fig. 2B). Pathways leading to the formation of
unlabeled DHAP are discussed in the Behavior of the SBT at
High CFX Concentrations Section. Control experiments
without either GLC or ATP did not produce any significant380 Biotechnology and Bioengineering, Vol. 106, No. 3, June 15, 2010amounts of DHAP (Fig. 2C), and verified that GLC was used
as the carbon source for DHAP synthesis.
Interestingly, no DHAP accumulation could be observed
when NADþ was not added to the SBT (Fig. 2D), although
ATP had been added to half-stoichiometric amounts
to GLC. This indicated that the enzymatic cascade was
disrupted because of the unavailability of the cofactor for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH).
Unavailability of NADþ would lead to accumulation of
GAP and a resulting equilibrium-induced shift of the
aldolase reaction to the side of FBP. In turn, this result
suggested that in the presence of NADþ the regeneration
pathway in the lower part of glycolysis was both, functional
and essential for DHAP accumulation. However, the
addition of LDH for the regeneration of NADþ from
NADH did not appear to be essential for the system’s
performance, because DHAP formation occurred indepen-
dently of LDH addition (see below for a more detailed
analysis).Behavior of the SBT at High CFX Concentrations
In order to reduce the reaction time of 5 h until maximum
DHAP concentrations were reached (Fig. 2A) the total
protein concentration of CFX was increased from 1 to
10 mg mL1. As expected, the time until maximum
DHAP concentrations was reduced significantly to 30 min
(Fig. 3A).
However, in contrast to the observations with CFX
concentrations of 1 mg mL1, a substantial 46% of the
DHAP produced were not labeled when the experiment was
carried out with 13C1-labeled GLC (Fig. 3B). In addition,
significant amounts of DHAP were produced in experiments
that contained either GLC but no ATP or ATP but no GLC
(Fig. 3C). The latter experiments indicated that there were
previously unconsidered substrates and pathways for the
production of DHAP, which had remained unnoticed
previously because of the high dilution of the CFX (appr.
200- to 300-fold based on intracellular protein concentra-
tion; Cayley et al., 1991). In this set of experiments, the
dilution of CFX was 10-fold less, and based on published
intracellular metabolite concentrations (Bennett et al.,
2009), ATP and NADþ concentrations in a 30-fold dilution
can be expected to be in the range of 0.3 and 0.1 mM,
respectively. This would explain GLC consumption and
DHAP production without addition of extra ATP (Fig. 3C)
or NADþ (Fig. 3D).
Unlabeled DHAP could be produced from non-GLC
sources, from GLC via the pentose–phosphate pathway
(PPP; Fig. 1) or by losing its label after synthesis. We could
not identify any biochemical reaction for the latter route
from the literature. Production via the PPP would require a
transfer of reduction equivalents from NADH to NADPþ,
probably via the transhydrogenase UdhA (Boonstra et al.,
1999; Sauer et al., 2004), because the first enzymes of the PPP
depend exclusively on NADPH (Fuhrer and Sauer, 2009).
Figure 2. The impact of process conditions and the genetic background on DHAP production using CFX with a total protein concentration of 1mgmL1. A: Comparison of
DHAP production and glucose consumption in WT- and tpiA::kan-derived CFXs. B: Analysis of the origin of DHAP using 13C1-glucose. C: DHAP production in CFX in the absence of
glucose or ATP. D: Production of DHAP in the presence and absence of additional NADþ and LDH.Via this route, the 13C1-label of GLC could be released
as CO2 by 6-phosphogluconate dehydrogenase (GND)
and would be no longer present in the subsequent PPP
intermediate fructose-6-phosphate (F6P), from which
DHAP could be formed along SBT reactions (Fig. 1).
In order to obtain an estimate of GLC flux through the
PPP, we analyzed representatively the activity of G6P-DH
under operating conditions of the reaction network. Under
low nicotinamide adenine dinucleotide conditions (1 mM),
G6P-DH activity was only high when NADPþ was supplied
in control experiments, not when NADþ was supplied.
When 5.75 mM NADþ was added to the reaction mixture,
G6P-DH activity was observed, but only at a high protein
concentration of 10 mg mL1. At lower NADþ concentra-
tions G6P-DH activity was reduced and no activity was
observed in the absence of NADþ (Table I). Consequently, itseems likely that a fraction of the unlabeled DHAP under
high protein and high NADþ conditions is still derived from
GLC but formed after channeling a part of the GLC through
the PPP. However, even under these conditions, the G6P-
DH reaction rate was eightfold lower in our assay than the
initial specific DHAP production rate in the corresponding
DHAP-production experiment, pointing strongly to
another source of unlabeled DHAP.Debugging of the Reaction Network for High
CFX Concentrations
As a substitute for GLC, compounds present in the CFX or
ATP itself could theoretically serve as sources for DHAP.
The initial ATP supply was varied by a factor of two in orderBujara et al.: DHAP Production in a System of Biotransformations 381
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Figure 3. Acceleration of DHAP production by using CFX with a protein concentration of 10mgmL1. A: DHAP production and glucose consumption. B: Analysis of the origin
of DHAP using 13C1-GLC. C: DHAP production in the absence of glucose or ATP. D: Production of DHAP in the presence and absence of additional NAD
þ and LDH.to determine the impact of initial ATP concentrations onto
DHAP formation in the absence of GLC. The time course of
DHAP-production showed a functional relationship to the
initial ATP concentration. Varying the initial ATPTable I. G6P-DH activity under operating conditions of the system and




activity mmol min1 g protein1
1 mM NADPþ 1a 71 4
5.75 mM NADþ 1a <0.1
5.75 mM NADþ 10b 6 0.4
0.575 mM NADþ 10b 1 0.1
0.0575 mM NADþ 10b 0.4 0.01
w/o NADþ 10b <0.1
aApproximately corresponding to a dilution of 1:300.
bApproximately corresponding to a dilution of 1:30.
382 Biotechnology and Bioengineering, Vol. 106, No. 3, June 15, 2010concentration between 23 and 5.75 mM led to a correspond-
ing variation in the final DHAP concentration (Fig. 4A), but
the yield of DHAP per added ATP remained nearly constant
(0.70, 0.66, and 0.63 mol mol1 for initial ATP concentra-
tions of 23, 11.5, and 5.75 mM, respectively). This was a
strong indication that ATP was a main substrate for DHAP
production in the absence of GLC.
A potential ATP degradation pathway leading to DHAP as
the final product consists of dephosphorylation of ATP to
AMP and subsequent hydrolysis by AMP-nucleosidase
(Amn) to ribose-5-phosphate (R5P) and adenine (A; Fig. 1),
the first step in the primary AMP degradation pathway
(Leung and Schramm, 1980). R5P can then enter the PPP,
where three molecules of R5P (two of which are first
converted to xylulose-5-phosphate by PPP enzymes) can
lead to two molecules of F6P and one molecule of GAP. In a
further step, F6P could be phosphorylated to FBP, which
Figure 4. Debugging of the reaction cascade: removing DHAP production from ATP and stabilization of AXP pools using 10mgmL1 protein concentration. A: Effect of
different initial ATP concentrations on DHAP production without glucose using tpiA::kan-derived CFX and (B) usingDamn tpiA::kan-derived CFX. C: The relative amount of ATP, ADP,
and AMP in a GLC metabolizing experiment was analyzed over the time course of the reaction using tpiA::kan- or Damn tpiA::kan-derived CFX.could then be converted to DHAP and GAP. The ADP
produced in the latter step could then be re-generated in the
lower glycolysis (Fig. 1). Taking stoichiometric coefficients
into account, this would lead to the following overall
reaction stoichiometry:
3ATP! 2DHAPþ 2GAPþ PYRþ 3Aþ 5Pi
This corresponds to a theoretical yield of YDHAP/ATP of
0.66 mol mol1, which is close to the observed yields for the
different initial ATP concentrations (Fig. 4A).
Because of this strong indication, a Damn tpiA::kan
knockout strain was constructed, which showed the same
growth deficient phenotype as the tpiA::kan single mutant
(mmax¼ 0.4 h1). In fact, the CFX derived from a Damn
tpiA::kan double knockout strain produced only lowamounts of DHAP, if GLC was not present and no longer
showed a functional relationship between initial ATP supply
and final DHAP concentrations (Fig. 4B) supporting the
notion that the prevention of Amn production disrupted the
pathway from ATP to DHAP. Finally, the AXP pool (the
sum of the concentrations of ATP, ADP, and AMP) could be
stabilized by introducing this gene deletion: the conversion
of GLC to DHAP in a Damn tpiA::kan mutant proceeded
with an AXP pool that was—within the limits of
measurement—stable, while the pool decreased to about
25% when CFX produced from a strain without the amn
mutation was used (Fig. 4C). Remarkably, the specific initial
DHAP production rate from GLC increased from
47 2mmol min1 g1 of protein for tpiA::kan-derived
CFX to 80 2mmol min1 g1 of protein for Damn
tpiA::kan-derived CFX. However, introducing the amnBujara et al.: DHAP Production in a System of Biotransformations 383
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Figure 5. Analysis of the origin of DHAP using 13C1-GLC using 10mgmL1 of CFX derived from Damn tpiA::kan-double mutant strains, either not washed (A) or washed (B).deletion into a tpiA-deficient strain did not completely
abolish DHAP production from other sources than GLC.Table II. The impact of reduced initial ATP concentrations on maximal
DHAP production in tpiA::kan- and Damn tpiA::kan-derived CFX.
ATP conc. (mM)
Maximum DHAP conc. (mM)
tpiA::kan CFX Damn tpiA::kan CFX
11.50 12 11.8
5.75 9 11
2.875 5.8 9.7Production of Unlabeled DHAP in the Damn tpiA::kan
Double Mutant
In order to comprehensively address the question of how
much DHAP is produced from GLC; 13C1-labeled GLC was
again supplied as substrate in an SBT using CFX from the
double mutant. Although the amount of unlabeled DHAP
decreased (Fig. 5A), unlabeled DHAP still contributed
substantially to the total amount and still exceeded the
amount that should theoretically have been produced after
passing G6P through the PPP instead of glycolysis. To
exclude that the unlabeled DHAP could simply be a result of
the conversion of metabolites still available from the CFX-
preparation, the CFX was washed prior to application. This
reduced the amount of unlabeled DHAP to about 25% of
total DHAP produced (Fig. 5B) and indicated that a certain
amount of unlabeled DHAP using unwashed CFX has a
metabolite origin with a molecular weight <10 kDa. This
could also explain GLC consumption and DHAP produc-
tion in the absence of ATP (Fig. 3C). Finally, we cannot
exclude that degradation products from macromolecules
>10 kDa, in particular of RNA, also contribute to the
formation of unlabeled DHAP.
In summary, these results illustrate the complexity of
using CFXs, especially if high CFX concentrations are
applied, and indicate three sources for potentially interfering
reactions: (i) cofactors supplied for SBT operation are
used for different purposes (DHAP formation from ATP);
(ii) utilization for formerly cytosolic small molecules
(reduction in DHAP formation when using washed CFX,
GLC consumption in the absence of ATP); and (iii)
degradation products from macromolecules as substrates.384 Biotechnology and Bioengineering, Vol. 106, No. 3, June 15, 2010From Stoichiometric to Catalytic Operation—
Optimization of ATP Concentrations
The design of the reaction network theoretically contains a
complete recycling system for ATP and NADH if no parallel
reactions take place. Hence, catalytic amounts of ATP
should be sufficient for a nearly complete conversion of GLC
to DHAP and lactate. The production of DHAP at a CFX
concentration of 10 mg mL1 using reduced initial ATP
concentrations was analyzed and compared between
tpiA::kan-and Damn tpiA::kan-derived CFX in order to
investigate the impact of amn deletion onto the overall
production capacity and to find the minimal ATP
concentration for sustained DHAP production.
Absolute DHAP concentrations were similar with a
tpiA::kan- and Damn tpiA::kan-derived CFX, if 11.5 mM
ATP were supplied. A reduction of the initial ATP supply
showed a strong impact onto DHAP production when
tpiA::kan-derived CFX was used, but not when Damn
tpiA::kan-derived CFX was used (Table II). These results
showed again the benefit of the amn knockout, which
enabled the use of 2.875 mM ATP for sustained DHAP
production, which is only 15% of the amount of ATP that
would be required to stoichiometrically produce the same
amount of DHAP from GLC without ATP regeneration.
Optimization of Cofactor Concentrations—NADR and
the Role of LDH
NADþ is required for the conversion of GAP to 1,3PG,
which is the first reaction for the regeneration of ATP in the
lower part of glycolysis. From the previously discussed
experiments, it was clear that (i) the regeneration pathway
was essential for DHAP production (Fig. 2D); and (ii)
NADþ, but not LDH, was required if CFX at 1 mg mL1 was
used (Fig. 2D); furthermore, in experiments with high CFX
concentration (10 mg mL1), neither NADþ nor LDH were
required (Fig. 3D), presumably because NADþ amounts
present in the CFX were enough for GAPDH activity.
The expandability of LDH for NADþ regeneration shown
earlier suggested the presence of alternative enzymes in the
CFX, which could regenerate NADH to NADþ. Analyzing
the stability of NADH in CFX confirmed that NADH wasFigure 6. NADH degradation capacity of CFX and optimization of NADþ concentration
1mgmL1. 1 mM NADH was added to CFX and its degradation was monitored. B: NADH stab
the indicated periods of time, then NADHwas added and its concentration after 10min was d
on DHAP production in the presence and absence of LDH.rapidly oxidized (Fig. 6A), with a specific rate of
approximately 260mmol min1 g1 of total protein in
CFX. Within 2.5 min, the NADH concentration was reduced
from 1 to approximately 0.25 mM, when it stopped
abruptly; presumably because of temperature sensitivity
(see below). This catalytic activity is actually sufficient for an
efficient regeneration of NADþ, since NADH is produced at
a maximum specific rate of 80mmol min1 g1 as calculated
on the basis of our maximum DHAP production rate using
the Damn tpiA::kan system and 10 mg mL1 of protein.
We also analyzed the NADþ regeneration capacity after
incubation of CFX for different periods of time at 378C in
order to verify that the NADþ regeneration capacity was
maintained sufficiently long. CFX with a protein concen-
tration of 1 mg mL1 was incubated at 378C for 15–120 min,
then NADH was added and its concentration after 10-min
incubation at 378C was determined. The analysis showeds for experiments using 1mgmL1 of CFX. A: NADH stability in tpiA::kan-derived CFX at
ility in tpiA::kan-derived CFX over time at 1 mgmL1. CFX was pre-incubated at 378C for
etermined. Ctrl: reaction buffer without CFX. C: Effect of reduced NADþ concentrations
Bujara et al.: DHAP Production in a System of Biotransformations 385
Biotechnology and Bioengineering
that the NADH oxidization capacity of the CFX decreased
over time (Fig. 6B). After 15-min incubation of the CFX at
378C, the capacity to oxidize NADH was reduced by about
75%, and after 60 min, NADH was almost completely stable.
These results agree well with the results displayed in
Figure 3D, where LDH could be completely omitted—
apparently, its originally intended role was fulfilled by the
remaining NADH-oxidation activities in the CFX.
However, this could not be expected for prolonged
experiments such as DHAP formation at lower protein
concentrations. Therefore, we determined the minimum
NADþ concentration in the presence and absence of LDH
for 1 mg mL1 CFX. NADþ could be reduced by a factor of
100 if LDH was present, while a reduction of NADþ by a
factor of only 10 in the absence of LDH led to already 50%
less DHAP at the end of the experiment. A 1,000-fold
reduction in NADþ impaired DHAP production regardless
of the addition of LDH (Fig. 6C). This was presumably
because the concentration of NADþ decreased to almost a
10th of the Km value of GAPDH (Km¼ 0.045 mM; Eyschen
et al., 1999), making this reaction the bottleneck in ATP
regeneration.
Without considering any follow up reactions (see below),
the entire system could be operated with an ATP supply of
2.875 mM and without the addition of NADþ and LDH if a
total protein concentration of 10 mg mL1 was used.Monosaccharide Synthesis
Since DHAP is an unstable molecule (Hettwer et al., 2002), it
is not an optimal end-product of the reaction cascade. It
should be rather used as a versatile building block for
carbohydrate synthesis in an aldolase catalyzed reaction, for
example, with RAMA (Fig. 1). To confirm that the SBT can
work effectively for preparative sugar synthesis, the aldolase-
catalyzed conversion of DHAP and butanal to TDHP was
chosen as a model reaction, since butanal is known as a good
substrate for RAMA and RAMA introduces the same
stereoconfiguration of vicinal diols as E. coli’s fructose-
bisphosphate-aldolase (FbaA; Bednarski et al., 1989) which
is the primarily used aldolase in E. coli grown on GLC as
substrate (Scamuffa and Caprioli, 1980). The latter enzyme
is supposed to accept only a very limited range of aldehydes
other than GAP (Fessner and Walter, 1996), which would be
an asset for using the DHAP-production cascade with
aldolases that produce a different stereoconfiguration.
However, at this preliminary stage we used only RAMA
in order to avoid any compromising of the diastereoselec-
tivity of the produced monosaccharide.
In a first step, DHAP was produced from GLC (11.1 mM)
using Damn tpiA::kan-derived CFX and only catalytic
amounts of ATP (2.875 mM ATP, 10 mg mL1 CFX). After
an initial DHAP production phase of 30 min, butanal
was added for the production of TDHP using E. coli’s
endogenous aldolase FbaA. However, 50% of the initial
DHAP was converted to TDHP within 90 min (Fig. 7A),386 Biotechnology and Bioengineering, Vol. 106, No. 3, June 15, 2010indicating that the E. coli aldolase could accept butanal as
aldehyde.
In order to obtain higher TDHP concentrations and faster
conversion of DHAP to TDHP, the amount of GLC was
increased by a factor of five (55.5 mM) and RAMA was
added while maintaining the ATP concentration constant
(2.875 mM). A one-step and a two-step process were used to
produce TDHP. Aldolase and butanal were either added
after an initial DHAP production phase (two-step, Fig. 7B)
or were present from the beginning (one-step, Fig. 7C). A
clear benefit of an additional butanal pulse was observed,
indicated by an increase of TDHP directly after the pulse
(Fig. 7B and C). However, in both cases the reaction stopped
before the entire amount of DHAP was depleted as reported
previously (Schoevaart et al., 1999). Similar concentrations
of DHAP (5 mM) and TDHP (23 mM) for the one- and
two-step process suggest that complete conversion of DHAP
to TDHP was limited by the thermodynamic equilibrium
between butanal, DHAP, and TDHP, which is known to be
less favorable for synthesis than the equilibrium between
DHAP, GAP, and FBP (Schoevaart et al., 1999).Discussion
The implementation of an efficient DHAP production
system for the production of an unnatural monosaccharide
based on E. coli’s modified glycolysis demonstrates that it is
easily possible to recruit in vitro a sufficiently insulated SBT
from an in vivo highly interconnected metabolic network
such as central carbon metabolism. GLC could be converted
to DHAP using CFX from a tpiA knockout strain, which
bisects the flux in the lower part of glycolysis. One equivalent
of DHAP could be produced per equivalent of GLC and the
remaining carbon backbone was used for cofactor regen-
eration enabling the use of catalytic concentrations of ATP
and NADþ. This potentially opens access to a large number
of interesting building blocks for fine chemistry.
The high yield of DHAP on GLC and the high degree of
ADP recycling indicate that only few intermediates of the
SBT entered anabolic pathways in the cell. A detailed
analysis of this phenomenon will be subject of a separate
investigation but the major reasons for this apparent
insulation can be expected to be the 30- and 300-fold
dilution, which reduces the concentrations of remaining
intracellular metabolites and cofactors below relevant levels
in the CFX, and the fact that the complex growth medium
suppresses the expression of a large number of potentially
interfering genes. These overarching considerations are
complemented by a number of system-specific considera-
tions, for example, the fact that NADH concentrations in the
discussed SBT were constantly low, reducing the potential
for DHAP removal through the glycerol-3-phosphate
dehydrogenase (GpsA), and the stoichiometric addition
of phosphate led to inhibition of the methylglyoxal synthase
(MgsA; Hopper and Cooper, 1971).
Figure 7. Production of 5,6,7-trideoxy-D-threo-heptulose-1-phosphate (TDHP) from GLC and butanal. A: Production of TDHP from 11.1 mM GLC in a two-step process using
FBA from E. coli. B: Acceleration of TDHP production from 11.1 mM GLC in a two-step process by adding RAMA and an additional butanal pulse. C: Two-step process for TDHP
production from 55.5 mM GLC using RAMA and two butanal pulses. D: Production of TDHP in a one-step process with RAMA and butanal present at the beginning of the reaction.Another major concern was the regeneration of ATP,
which was impaired by ATP degradation through enzymes
that were not part of the pathway. Deletion of the amn gene
reduced this effect substantially. Amn was recently shown to
be involved in maintaining intracellular ATP levels: its
deletion resulted in elevated ATP levels because the
degradation pathway of AMP was impaired (Morrison
and Shain, 2008). Although the conversion of ATP to ADP
and AMP can still occur, it will probably occur more slowly
in an amn mutant, since AMP is not constantly removed
from the system. Consequently, the improved system’s
performance of the CFX derived from the amn mutant can
be explained by an increased availability of ATP. In addition
to the effect of Amn, ATP is dephosphorylated to ADP
and AMP, presumably by phosphatases and other ATP
metabolizing reactions, which is a well-known phenomenon
in CFX-based systems (Kim and Choi, 2000). Providingenergy in the form of ATP to cell-free systems is a general
problem and several energy sources have been used in order
to improve performance and to reduce costs (Kim and
Swartz, 2000; Kim et al., 2008). Although ATP regeneration
operated rather efficiently in the glycolysis-based SBT, it did
not achieve complete regeneration. To address this problem,
we are currently working on the comprehensive analysis of
major phosphatase activities in CFX in order to design an
improved strain for cell-free applications.
Finally, a future concern over the implementation of SBTs
might originate from two potentially contradicting require-
ments: on one hand, an insulated SBT requires the absence
of specific enzyme activities—in the case discussed here, for
example, TpiA—while the cheap production of the CFX by
cultivation (e.g., by growth on a mineral medium with
a cheap carbon source) requires the presence of these
activities. Generally, tpiA knockout strains show a growthBujara et al.: DHAP Production in a System of Biotransformations 387
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defect on GLC-mineral medium (Fong and Palsson, 2004;
Fong et al., 2006) due to the bisection of glycolytic
intermediates downstream of FBP and the resulting reduced
flux of metabolites through the lower part of glycolysis
(Fong et al., 2006) and the production of methylglyoxal
which is toxic for the cell (Ferguson et al., 1998). In this
study, the growth impaired phenotype was partly compen-
sated by adding yeast extract to the culture which allowed
slow growth. However, to generalize the concept of
insulating complex pathways from CFXs, a simple knockout
strategy might no longer be feasible, not least of all because
multiple knockouts might lead to a lethal phenotype that
cannot be recovered by medium engineering. In order to
solve this problem, strategies for the simple but selective
removal of specific enzyme activities are currently under
investigation in our laboratory.
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